- Home
- BIIB vs MKC Comparison
BIIB vs MKC Comparison
Compare BIIB & MKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- MKC
- Stock Information
- Founded
- BIIB 1978
- MKC 1889
- Country
- BIIB United States
- MKC United States
- Employees
- BIIB N/A
- MKC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- MKC Packaged Foods
- Sector
- BIIB Health Care
- MKC Consumer Staples
- Exchange
- BIIB Nasdaq
- MKC Nasdaq
- Market Cap
- BIIB 18.8B
- MKC 19.5B
- IPO Year
- BIIB 1991
- MKC N/A
- Fundamental
- Price
- BIIB $125.00
- MKC $75.60
- Analyst Decision
- BIIB Buy
- MKC Buy
- Analyst Count
- BIIB 27
- MKC 8
- Target Price
- BIIB $188.17
- MKC $84.13
- AVG Volume (30 Days)
- BIIB 1.3M
- MKC 2.3M
- Earning Date
- BIIB 07-31-2025
- MKC 06-26-2025
- Dividend Yield
- BIIB N/A
- MKC 2.37%
- EPS Growth
- BIIB 26.39
- MKC 4.75
- EPS
- BIIB 10.12
- MKC 2.87
- Revenue
- BIIB $9,816,400,000.00
- MKC $6,742,800,000.00
- Revenue This Year
- BIIB N/A
- MKC $2.34
- Revenue Next Year
- BIIB N/A
- MKC $3.49
- P/E Ratio
- BIIB $12.41
- MKC $26.42
- Revenue Growth
- BIIB 1.59
- MKC 0.89
- 52 Week Low
- BIIB $110.04
- MKC $69.00
- 52 Week High
- BIIB $238.00
- MKC $86.24
- Technical
- Relative Strength Index (RSI)
- BIIB 45.14
- MKC 57.37
- Support Level
- BIIB $123.21
- MKC $73.35
- Resistance Level
- BIIB $129.27
- MKC $78.16
- Average True Range (ATR)
- BIIB 3.00
- MKC 1.49
- MACD
- BIIB -0.77
- MKC 0.34
- Stochastic Oscillator
- BIIB 21.06
- MKC 67.74
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About MKC McCormick & Company Incorporated
In its 135-year history, McCormick has become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond consumers, McCormick's customer base includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers. And its reach is extensive, with nearly 40% of sales generated beyond its home turf to 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula, among others.